DiaSorin S.p.A. (LON:0GZX)

Market Cap	4.20B
Revenue (ttm)	1.01B
Net Income (ttm)	162.38M
Shares Out	n/a
EPS (ttm)	3.01
PE Ratio	25.88
Forward PE	19.46
Dividend	1.01 (1.10%)
Ex-Dividend Date	May 19, 2025

Volume	15,093
Average Volume	9,148
Open	94.50
Previous Close	94.16
Day's Range	91.77 - 94.62
52-Week Range	76.24 - 112.10
Beta	0.25
RSI	35.77
Earnings Date	Jul 31, 2025

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR